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JENKS, B. G., B. M. L VERBURG VAN KEMENADE, M. C. TONON AND H. VAUDRY. Regulation of biosynthesis and 
release of pars intermedia peptides in Rana ridibunda: Doparnine affects both acetylation and release of a-MSH. PEP- 
TIDES 6(5) 913-921, 1985.--Dopamine is likely an important physiological melanotropin release-inhibiting factor in am- 
phibians. This study concerns the effects of dopamine on the biosynthesis and release of peptides from the pars intermedia 
of the frog Rana ridibunda. Our results show that this secretagogue has no immediate ffects on either the rate of 
biosynthesis of pro-opiomelanocortin nor on the direction of processing of this prohormone. Pulse-chase xperiments 
revealed that dopamine inhibited the release of all newly synthesized POMC-related peptides in a dose-dependent manner. 
For each dopamine concentration tested, the degree of inhibition exerted on the release of the various newly synthesized 
peptides by a given concentration f secretagogue was approximately the same, with the exception of that found for the 
c~-MSH related peptides. Analysis of the release of these melanotropins was complex because dopamine not only inhibited 
their release but also, either directly or indirectly, inhibited the acetylation reaction which converts des-Na-acetyl a-MSH 
to a-MSH. Dopamine was shown to be less potent in inhibiting the release of des-Na-acetyl a-MSH than inhibiting release 
of the acetylated form of the peptide. In amphibians a preferential release of the less-bioactive non-acetylated form of MSH 
under inhibitory conditions induced by dopamine may be of physiological importance. 
Pro-opiomelanocortin Melanotropin Acetylation Dopamine Pars intermedia Pulse-chase 
Biosynthesis High performance liquid chromatography Amphibian Rana ridibunda 
PRO-OPIOMELANOCORTIN (POMC) is a multifunctionai 
protein which, through tissue-specific processing, can give 
rise to a number of bioactive peptides including adrenocor- 
ticotropic hormone (ACTH), a-melanocyte-stimulating hor- 
mone (a-MSH) and fl-endorphin [7, 9, 15]. Coordinate regu- 
lation of the release of POMC-related peptides from 
POMC-producing cells was proposed by Guillemin et al. ]l l] 
on the basis of their observation that stress-induced leva- 
tions in plasma levels of ACTH were accompanied by paral- 
lel elevations in circulating levels of immunoassayable 
/3-endorphin. This concept of coordinate regulation is sup- 
ported by the results of a number of in vitro studies con- 
ducted with a mouse corticotrophin-producing tumor cell 
[1, 17, 21] and with corticotrophs of the ade- 
nohypophysis of the rat [25, 26, 31], mouse [l] and cow 
[2]. Radioimmunoassays of peptides released from these 
POMC-producing cells revealed that secretion of peptides 
derived from the prohormone occurred in parallel under both 
~Requests for reprints hould be addressed to H. Vaudry. 
basal and acute release-stimulatory or release-inhibitory 
conditions induced by the addition of secretagogues to the 
incubation media. Evidence for non-coordinated or differen- 
tial regulation of release of peptides from POMC-producing 
cells, whereby secretagogues can selectively stimulate or 
inhibit one group of POMC-related peptides over another, is 
less well documented. Randle et al. [24] reported a differen- 
tial control of release of POMC-derived peptides from the 
pars intermedia of the rat by serotonin. They suggested that 
this differential regulation was achieved by intervention of
the secretagogue with the direction of processing of POMC. 
Alternatively, as the rat lobe is known to contain two cell- 
types [29], the differential control might reflect differences in 
the regulation of these cells. In the amphibian Xenopus 
laevis it has been shown that the/3-adrenergic agonist iso- 
proterenol selectively inhibits the release of a POMC-related 
peptide,/3-1ipotropin, from the pars intermedia of this spe- 
cies [19,20]. The data suggested the existence of heteroge- 
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FIG. 1. (a) Examples of HPLC profiles of radiolabelled products released to the incubation medium during pulse-chase experiments with 
neurointermediate lobes ofRana ridibunda. Each example is from a different experiment using different lots of frogs. In all cases a mixture of 
radioactive amino acids was used in the labelling. The most common pattern is given in the upper profile (profile lacks product At. (b) HPLC 
profile for lobes and medium following a pulse-chase experiment with ['~H]-Iysine. The radioactive profile shown was obtained by determining 
the radioactivity ina 20 t~l sample of each 1 ml HPLC fraction. Fractions containing product llI and product IV were used in the characteriza- 
tion studies hown in Fig. 2. Note that products III and IV are restricted to the incubation medium and that these lobes failed to synthesize 
product A. The HPLC elution gradient used to produce all the profiles in this figure is shown in the upper ight profile (% secondary solvent. B). 
neous pools of POMC-related peptides, possibly reflecting 
two cell types. The involvement of a fl-adrenergic mech- 
anism in the regulation of the Xenopus pars intermedia has 
never been established and thus the physiological signifi- 
cance of the above observation remains unclear. 
In amphibians, there is considerable evidence to indicate 
that the neurotransmitter dopamine is an important physi- 
ological factor involved in the regulation of the pars inter- 
media [4, 10, 18, 30]. In Rana ridibunda, release of im- 
munoreactive MSH is inhibited in a dose-dependent manner 
by the dopamine agonist apomorphine and this inhibitory 
action is blocked by the dopamine receptor antagonist halo- 
peridol [30]. We have recently completed an in vitro study of 
the biosynthesis of peptides in pars intermedia of this same 
species [34]. Biosynthesis commenced with the production 
of a 36K (K=kilodalton) prohormone during a pulse- 
incubation i  radioactive amino acids. In subsequent chase- 
incubations the radioactive prohormone was cleaved to 
produce a number of small peptides including y-MSH, des- 
Nc~-acetyl a-MSH, corticotropin-like intermediate lobe pep- 
tide (CLIP) and an endorphin-like peptide. Following their 
biosynthesis the radioactive peptides were slowly secreted 
to the incubation medium. Pulse-chase analysis of the re- 
lease of these peptides has an advantage over other tech- 
niques, such as radioimmunoassays, in that the release of all 
peptides derived from POMC can be studied simultaneously. 
In the present investigation we have applied this technique to 
examine the effects of dopamine on the release of POMC- 
related peptides ynthesized by the frog pars intermedia. For 
our analysis, it was crucial to first determine if dopamine has 
any immediate ffect on the biosynthesis or the direction of 
intracellular processing of the prohormone. Therefore, ex- 
periments were also conducted to study the effect of 
dopamine on the in vitro incorporation of radioactive amino 
acids into the POMC-related peptides. 
METHOD 
Animals 
Adult male frogs (Rana ridibunda) were purchased from 
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FIG. 2. Characterization f radiolabelled products IlI and IV. The HPLC gradient used in these studies is given in the lower right (% 
secondary solvent B) and the elution position of synthetic c~-MSH and sulfoxidated a-MSH is indicated. NaOH treatment was given to remove 
potential O-linked acetyl groups and H._,O._, treatment was given to form potential sulfoxide forms of the peptides. 
Courtard, Saint-Hilaire de Riez, France. The animals were 
maintained in plastic tanks on a black background with con- 
stant illumination for one week prior to being used in the 
experiments. The purpose of the black-background a apta- 
tion was to induce high rates of peptide biosynthesis n the 
pars intermedia [34]. 
Characterization of Melanotropins 
The pars intermedia of Rana synthesizes the non- 
acetylated form of a-MSH (designated product 11 in a previ- 
ous study [34]) which is subsequently modified to form two 
structurally closely related peptides (designated products III 
and IV). To establish the acetylation status of these latter 
two peptides, or to determine if one of them might represent 
the sulfoxide form of the other, radiolabelled samples of 
these peptides were treated with NaOH (a treatment which 
removes the O-linked acetyl group from N, O-di-acetyl 
~-MSH) or with H.,O~ (to form potential sulfoxide derivatives 
of these peptides). To obtain the radiolabelled peptides, ten 
neurointermediate lobes of Rana were incubated for 8 hr at 
22°C in 200/xl incubation medium containing 250 tzCi [:~H]- 
lysine (90 Ci mmole ') and, following a brief rinse, were 
chase-incubated for 15 hr in medium containing L-lysine (2 
mM). Condition for the incubations were the same as those 
reported previously [34] and briefly summarized below. Fol- 
lowing incubation the lobes were extracted in 1 ml 0.1 N 
HCI, the medium was acidified to 0.1 N in HC1, and both the 
lobe extract and medium were submitted to high perform- 
ance liquid chromatography (HPLC), as outlined below. A 
20 izl sample of each 0.5 min HPLC-fraction (volume of each 
fraction was 1 ml) was taken, 2 ml scintillation fluid was 
added to each sample and the radioactivity in each sample 
determined. From the radioactive profiles obtained those 
fractions containing radiolabelled products III and IV were 
determined, these were divided into a number of samples, 20 
~g poly-pep (Sigma) was added to each sample and they 
were dried by vacuum centrifugation. These peptides were 
then submitted to HPLC, either as untreated samples or 
treated with 50 tzl 0.01 N NaOH (30 min, 37°C) or with 50 tzl 
30% H2Oe (5 min, room temperature) prior to chromato- 
graphic analysis. Following HPLC the amount of radioactiv- 
ity in each HPLC-fraction was determined. The elution 
position of synthetic a-MSH (Sigma) and its sulfoxide form 
(produced by treating the synthetic peptide with H._,O._,) were 
determined by submitting these peptides to HPLC and assay- 
ing each fraction with a radioimmunoassay for a-MSH. 
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TABLE 1 
EFFECTS OF DOPAMINE ON THE BIOSYNTHESIS AND 
PROCESSING OF POMC-RELATED PEPTIDES IN 
NEUROINTERMEDIATE LOBES OF RANA RIDIBUNDA 
Radioactivity (CPM -4- SEM) 
Peptide Control (n=5) Dopamine(n=6) 
y-MSH (I) 4,283 _+ 222 4,674 _+ 651 
des-Not-acetyl c~-MSH (II) 2,650 _+ 123 3,164 _+ 461 
y-MSH intermediate (V) 3,076 _+ 419 3,363 _+ 399 
endorphin-like-peptide 6,918 _+ 828 9,058 _+ 1,076 
(VI) 
CLIP (VII) 6,962 ___ 950 8,351 _+ 1,303 
POMC/I6K fragment (XI) 22,247 _+ 3,243 23,352 _+ 3,635 
Lobes were pre-incubated in absence (control) or presence of 
dopamine (10 -5 M) for 2 hr and then incubated for 4 hr in radioactive 
amino acids ([3H]-lysine, [3H]-leucine mixture). Treatment with 
dopamine was continued uring radioactive labeling. Following incu- 
bations each lobe was extracted and the extract submitted to HPLC. 
From the HPLC profile obtained, the radioactivity corresponding to 
various POMC-related peptides were then determined for each lobe. 
Results given are the mean (-+SEM) of radioactivity incorporated into 
the newly synthesized peptides. Analysis with Student's t test show 
that there is no significant difference (p >0.10) between level of indi- 
vidual products in the control and dopamine treated groups. 
Conditions for the radioimmunoassay have been reported 
elsewhere [32]. 
Analysis of POMC Biosynthesis and Processing 
Because it was our intention to quantify the effect of 
dopamine upon the incorporation of radioactive amino acids 
into POMC-related peptides, animals of approximately the 
same size (40 g) were selected for these experiments. The 
frogs were decapitated between 0800-0900 hr and the 
neurointermediate lobes were dissected out immediately. 
The lobes were pre-incubated for 2 hr in 500/~1 normal incu- 
bation medium (controls) or in 500 tzl incubation medium 
containing 10 -5 M dopamine. The composition of the incu- 
bation medium was as follows: 112 mM NaCI, 2 mM CaC12, 
2 mM KC1, 15 mM Hepes, 2 mg/ml glucose, 0.3 mg/ml bovine 
serum albumin and 1 p~g/ml ascorbic acid. Cell incubations 
were conducted at 22°C and the incubation medium was 
gassed for 15 min with O2-CO2 (95:5) and pH adjusted to 7.3 
prior to use. Following the pre-incubation the lobes were 
incubated individually in 50/xl of medium containing 40/~Ci 
[3H]-lysine (90 Ci mmole ~, Amersham) and 40 /zCi ['~H]- 
leucine (50 Ci mmole -j ,  Amersham) for 4 hr. Dopamine (10 -5 
M) was also present in the medium of the dopamine-treated 
group during these later incubations. The lobes were then 
individually homogenized in 500/zl chilled 0.1 N HCI and 
each extract stored frozen until analyzed by HPLC. 
Analysis of Release of POMC-Related Peptides 
Neurointermediate lobes were incubated for 4 hr in 65/xl 
medium containing 40 /zCi each of [3H]-lysine (90 Ci 
mmole-l), [3H]-leucine (50 Ci mmole-l), [3H]-phenylalanine 
(115 Ci mmole-~) and ['~H]-tyrosine (45 Ci mmole-~) all pur- 
chased from Amersham. Following this pulse-incubation 
each lobe was rinsed three times in medium containing 2 mM 
lysine, 2 mM leucine, 2 mM phenylalanine and 2 mM 
tyrosine (chase-incubation medium). Lobes were then incu- 
bated individually for 6 hr in normal medium (control) or in 
medium containing dopamine (10 -s M, 10 -7 M, l0 " M or 
10 -5 M). In each case the volume of the chase-medium was 
200 ~1 and it was replaced with fresh medium every 2 hr 
during the course of the chase incubation. The collected 
medium was acidified to a final concentration of 0.1 N HCI 
and frozen immediately. At the end of the incubations each 
lobe was extracted and both lobe extracts and media were 
kept frozen until HPLC analysis. 
High Perfi~rmance Liquid Chromatography 
Separation of newly synthesized radioactive peptides was 
accomplished by reverse-phase HPLC using a Spherisorb 10 
ODS-column (Chrompack) with 0.5 M formic acid, 0.14 M 
pyridine (pH 3.0) as the primary solvent and a gradient elu- 
tion established with l-propanol. A flow rate of 2.0 ml/min 
was used and 0.5 min fractions were collected. To each frac- 
tion 4 mi of scintillation liquid (Scintillator 299, Packard) was 
added and the radioactivity determined on a liquid scintilla- 
tion analyser. The media collected from individual lobes dur- 
ing the pulse-chase experiments were pooled prior to HPLC 
analysis. For comparing the radioactivity associated with 
each peak a standard procedure was adopted whereby the 
two highest cpm-values of each peak in each HPLC-profile 
were taken. 
Statistics 
Results were analyzed for significance with the Student's 
t test. All values are reported as mean_+SEM except where 
data are from individual animals. 
RESULTS 
Identification of Acetylated Forms of MSH 
In reviewing our HPLC incubation-media profiles ob- 
tained from a number of biosynthetic studies using different 
lots of frogs, all purchased from the same commercial 
supplier, it is evident that with respect o products III and 
IV, differences in pattern of release occur (Fig. la). The 
most common pattern is that both products III and IV are 
present in the incubation medium (Fig. la, top profile), a 
situation that was the rule in our previous studies [33,34]. 
Another pattern found is that product III is present, product 
IV is absent, and a new product, labelled A, is present (Fig. 
la, middle profile). This is the pattern found in the present 
studies (see Fig. 3). A third pattern, only occasionally 
encountered, is characterized by the presence of products 
III, IV and A (Fig. la, bottom profile). In attempting to 
isolate radiolabelled peptides for further characterization, 
the lobes used synthesized products III and IV but failed to 
produce product A (Fig. Ib). Thus, at present, it is not 
possible to further characterize this latter peptide. The pres- 
ence of products III and IV were restricted to the incubation 
medium, a characteristic that they hold in common with 
product A (see for example, Fig. 3). 
Previous tryptic mapping studies [33] showed that prod- 
ucts II, III and IV all contain the ACTH(8-13)NH2 tryptic 
fragment, as expected for c~-MSH related peptides. Product 
II also generated the ACTH(1-7) fragment and thus its iden- 
tity as the non-acetylated form of c~-MSH (des-Nc~-acetyl 
o~-MSH) was established. The N-terminal tryptic fragments 
of both product III and product IV had longer HPLC reten- 
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FIG. 3. Pulse-chase analysis of the release of POMC-related peptides from the neurointermediate lobe ofRana ridibunda. Lobes were given a 
4 hr pulse-incubation i  medium containing a mixture of {3H]-lysine, [3H]-Ieucine, [3H]-phenylalanine and [aH]-tyrosine and then chase- 
incubated for 6 hr in normal medium (control) or in medium containing 10 -~ M dopamine. Lobe extracts and media were then submitted to 
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solvent, B). Note the expanded scale of medium profiles. 
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(product III). The percent of the MSH present in the acetylated form relative to total MSH (lobe plus medium) are given for the control and 
dopamine treated tissue. Values are the average (_+SEM) obtained from the same experiments a those described above. 
o 
WI, i 
Key 
~3 inactive acetytating 
enzyme 
• active acetytating 
enzyme 
o des-Ncc-acetyt c¢-MSH 
• a-MSH 
FIG. 5. Possible mechanisms whereby dopamine can exert a more potent inhibition on the release of a-MSH than on the release of 
des-Na-acetyl a-MSH. (a) Independent compartments in which secretory granules are predestined tofollow an acetylation-linked pathway or 
a non-acetylation pathway. (b) Independent secretory pathways for the release of acetylated and non-acetylated melanotropins from a single 
compartment or pool. (c) Independent action ofdopamine on the acetylation system and the secretory process. The thickness of the arrow for 
the effect of dopamine (DA) is intended to give an indication of the relative strength ot the inhibitory action exerted by the secretagogue. Thick 
arrows indicate stronger inhibitory action and the arrows are dotted within the cells to indicate the probable involvement of intracellular 
second messenger mechanisms. (Note: while the acetylation enzyme is shown to be associated with the secretory granule membrane and cell 
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DOPAMINE EFFECTS ON ACETYLATION AND RELEASE OF a-MSH 919 
tion times than the ACTH(I-7) peptide and in fact had elu- 
tion characteristic very similar or identical to N-acetyl 
ACTH(1-7). It was suggested that product IV was c~-MSH 
and that product III could be the sulfoxide form of this pep- 
tide. In the present study, where a shallower HPLC elution 
gradient is used to achieve higher resolution of these pep- 
tides (Fig. 2), it is evident that radiolabelled product Ill 
elutes in the position of c~-MSH. Moreover, with H20.., 
treatment the elution position of this product shifts to that of 
the sulfoxide form of a-MSH. NaOH treatment has no effect 
on the elution characteristic of product III. This same treat- 
ment on radiolabelled product 1V generates a peptide that 
elutes in the position of product III. Finally, treatment of 
product IV first with NaOH, and subsequently with H~O~, 
gives a product with elution characteristics identical to sul- 
foxidated a-MSH. Altogether we conclude that product III is 
monoacetylated a-MSH (N-acetyl a-MSH) and that product 
IV is the diacetylated form of the peptide (N, O-diacetyl 
a-MSH). 
Effects of Dopamine on Biosynthesis and Processing 
of POMC 
Table 1 gives the amount of POMC-related peptides yn- 
thesized by control and dopamine-treated tissue. The char- 
acterization and identification of these HPLC-resolved pep- 
tides, which involved selective amino acid incorporation, 
immunoprecipitation a d tryptic and chymotryptic mapping 
has been reported earlier [34]. The radioactive peptides yn- 
thesized by the frog neurointermediate lobe were numbered 
I-XI according to their elution position from the HPLC col- 
umn and the roman numerals given in the table refer to this 
previous designation. As this study involves an analysis of 
lobe-peptides only, those products whose presence is re- 
stricted to the incubation medium (product III, IV and A) 
[33,34] are missing in this analysis. The identity of newly 
synthesized products VII I -X remains to be established and 
they were therefore xcluded from the table. Since HPLC 
failed to separate POMC from the N-terminal 16K-fragment 
of this prohormone these proteins are analyzed together 
(peak XI). 
No significant difference was found in the total radioac- 
tivity incorporated into POMC-related peptides between the 
control (46,150_+5,500 cpm) and dopamine-treated group 
(57,500+-11,050 cpm) (p>0.05). Also, when the level of 
radioactivity in individual products were compared no signif- 
icant differences were found (Table 1). 
EJfects of Dopamine on the Release of 
POMC-Related Products 
Figure 3 gives an example of the HPLC analysis of a 
pulse-chase experiment for a control and a dopamine-treated 
lobe. The results presented are from frogs of approximately 
the same size. It is evident hat for each newly synthesized 
peptide, the absolute amount released to the incubation 
medium by the dopamine-treated lobe is less than that re- 
leased by the control obe. Note that the relative reduction in 
the level of des-Na-acetyl a-MSH (product II) in the incuba- 
tion medium of the dopamine treated lobe compared to the 
medium of the control lobe is much less than the reduction 
displayed by the other peptides. Thus, product II becomes a
major product in the dopamine medium profile. 
Because it proved impossible to use animals of the same 
size throughout he pulse-chase xperiments, the relative 
levels of release of each peptide, defined as the fraction of 
the total amount of radioactive peptide (lobe plus medium) 
that is secreted to the medium was considered in the further 
analysis of these data. In this manner it was possible to com- 
pare release between different sized lobes which, because of 
their size differences, had different levels of total radioactive 
incorporation. For the a-MSH-related peptides (products II 
and Ill) the release of each peptide was determined relative 
to the total level of radioactive peptides (lobe plus medium) 
associated with this group of peptides. 
Given in Fig. 4 A is the effect of dopamine, at concentra- 
tions ranging from 10 ~ M to l0 5 M, on the rate of release of 
y-MSH (product I), y-MSH intermediate (product V), 
endorphin-like-peptide (product VI) and CLIP (product VII) 
expressed as a percent of the relative rate of release dis- 
played by control obes. Dopamine suppressed the release of 
all these peptides in a dose-dependent manner and, at each 
concentration of dopamine tested, there was no significant 
difference in the degree of inhibition achieved for each pep- 
tide. 
The effects of dopamine on the release of a-MSH-related 
peptides is given in Fig. 4 (B). While dopamine suppressed 
the release of both the non-acetylated (product II) and the 
acetylated peptide (product III) in a dose-dependent manner, 
the degree of inhibition achieved was not the same for both 
peptides. At each concentration of dopamine tested the sec- 
retagogue was more potent in inhibiting the release of the 
acetylated form of the peptide than in inhibiting the non- 
acetylated peptide. 
In control experiments a-MSH represent 17.8% of the 
total amount of newly synthesized a-MSH plus des-Na- 
acetyl a-MSH (Fig. 4 (C)). Incubation in the presence of 
dopamine reduced the relative amount of acetylated peptide 
and this reduction occurred in the dose-dependent manner. 
DISCUSSION 
Previous biosynthetic studies have shown that neuroin- 
termediate lobes of the frog Rana ridibunda synthesize two 
peptides (products IIl and IV) which, on the basis of their 
amino acid composition, their bioactivities and immunoac- 
tivities, and their tryptic mapping charactistics were desig- 
nated as acetylated forms of MSH [33,34]. The fact that 
product IV converts to product III at high pH, a treatment 
shown to remove the O-linked acetyl group from N, 
O-diacetyl c~-MSH [28], now establishes product IV as the 
diacetyl form of MSH and product III as the monoacetylated 
peptide. From the results of numerous biosynthetic studies it 
is evident hat the relative level of production of these acety- 
lated peptides can differ between groups of frogs, the most 
common pattern being synthesis of both the monoacetylated 
and diacetylated peptides. Occasionally, as is the case with 
the neurointermediate lobes used in the present study, only 
the monoacetylated peptide is formed. One feature these 
acetylated forms of MSH have in common is that their pres- 
ence is restricted to the incubation medium. This observa- 
tion has lead us to propose that acetylation of MSH in the 
pars intermedia of Rana is associated with the release proc- 
ess [33]. Possibly, electrochemical changes in the micro- 
environment of the secretory granule during the process of 
exocytosis activates an acetylation system for the 
N-terminal acetylation of the peptide. It is evident that, in 
vitro at least, acetylation of the peptide population is not 
complete as some non-acetylated MSH (product II) is always 
present in the incubation medium. 
The frogs used in the present study, while lacking the 
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diacetylated form of a-MSH, synthesized a new peptide, 
designated product A. That there is probably no relationship 
between the lack of diacetylated a-MSH and the presence of 
this new peptide is indicated by the fact that we have found 
some frogs capable of synthesizing both diacetyl a-MSH and 
product A. As with the acetylated melanotropins, the pres- 
ence of product A was restricted to the incubation medium, 
suggesting that it could represent yet another form of MSH. 
We have been unable to obtain sufficient quantities of this 
peptide for characterization a d therefore, in considering 
a-MSH related peptides in the present study we have re- 
stricted our attention to only the fully characterized prod- 
ucts, namely des-Na-acetyl a-MSH (product II) and 
monoacetylated a-MSH (product III). 
It has been shown that factors which influence the secre- 
tory process in POMC-producing cells can also affect the 
rate of biosynthesis of the prohormone. For example, dex- 
amethasone, a synthetic glucocorticoid known to inhibit the 
release of POMC-related peptides from the anterior pituitary 
[1,25], also suppresses transcription of the POMC gene 
[3,27]. More relevant o the present investigation is the ob- 
servation that chronic treatment of rats with dopamine 
agonists decreases the levels of POMC mRNA in the inter- 
mediate lobe of the rat [5] while treatment with antagonists 
increases mRNA levels [5,16]. Although dopamine has been 
shown to have a very rapid inhibitory effect on the secretion 
of melanotropins from the pars intermedia of Rana [30], it is 
clear from the present results that it had no direct effect on 
biosynthetic activity in the lobe. In addition, we observed 
that dopamine had no effect on the HPLC profile of newly 
synthesized peptides, which indicates that the secretagogue 
does not alter the direction of intracellular processing of 
POMC within the time constraints of our in vitro incuba- 
tions. Thus, in the short term at least, the effects of 
dopamine on the pars intermedia of Rana are restricted to 
those exerted on the release process. 
Our results show that dopamine inhibits the release of all 
newly-synthesized POMC-related peptides in a dose- 
dependent manner. Moreover, the degree of inhibition of 
release xerted by any given concentration of dopamine was 
approximately the same on each peptide. This later observa- 
tion was true for all products except hose related to a-MSH 
and was observed over a wide range of dopamine concentra- 
tions. Thus, these results in general support he concept of 
coordinate regulation of release of peptides from POMC- 
producing systems. 
The fact that acetylation of MSH is associated with the 
release process has made the analysis of the release of 
ct-MSH related peptides more complex than that of the other 
peptides. Most surprising was the finding that dopamine had 
a significantly more potent inhibitory effect on the release of 
the acetylated form of a-MSH compared to its effect on the 
release of des-Nct-acetyl a-MSH. Along these lines, Ham et 
al. [13,14] have recently shown that dopamine may alter the 
post-translational processing of POMC-related peptides. In 
particlular, dopaminergic agents modify the acetylation of 
/3-endorphin-derived peptides in rat pars intermedia cells in 
culture. 
There are a number of possible explanations for the dif- 
ferential effect of dopamine on the release of the acetylated 
and non-acetylated melanotropin (see Fig. 5). The MSH 
destined for release in the non-acetylated form could be 
sequestered in a different compartment or "release pool" 
than MSH destined for acetylation (Fig. 5 (a)). The former 
compartment would be less sensitive to inhibition by 
dopamine and thus, the release of des-Na-acetyl a-MSH is 
favoured under the inhibitory conditions induced by 
dopamine. An alternative on this theme would be a single 
compartment of peptides with two independent intracellular 
pathways for secretion (Fig. 5 (b)). One pathway, in which 
acetylation is associated with secretion of melanotropin, is
more sensitive to dopamine inhibition than that displayed by 
the other pathway which releases primarily des-Na-acetyl 
a-MSH. Another, perhaps simpler explanation, is that 
dopamine could have an inhibitory action on the acetylation 
enzyme or enzyme system independent of its inhibitory ac- 
tion on the secretory process (Fig. 5 (c)). An independent 
inhibition on the acetylation system could favour the release 
of des-Na-acetyl a-MSH relative to the release of the acety- 
lated peptide. 
The present data do not allow us to give preference to any 
one of the proposed mechanisms over another. The obser- 
vation, however, that release of des-Na-acetyl a-MSH is 
favoured over the acetylated peptide under inhibitory condi- 
tions induced by dopamine may be of physiological signifi- 
cance. The non-acetylated form of the peptide is known to be 
melanotropically less-potent [8,12]. In living frogs the 
melanotrophs of the pars intermedia of white-background 
adapted animals are under dopaminergic nhibition. Conse- 
quently, circulating levels of melanotropins are low and the 
skin displays a pale coloration. A possible contribution to 
this pallor could be that in such animals any MSH released 
would be in the less melanotropic non-acetylated form. Both 
the groups of O'Donohue [6, 22, 23] and Smyth [35,36] have 
proposed that regulation of N-terminal acetylation reactions 
could constitute an important control point for modulation of 
the secretory signal from POMC-producing cells. An under- 
standing of the regulation of acetylation of melanotropins in 
the pars intermedia of amphibians may make an important 
contribution in furthering this concept. 
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